Xu Hanqiao, Kurohara Takashi, Ohoka Nobumichi, Tsuji Genichiro, Inoue Takao, Naito Mikihiko, Demizu Yosuke
National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan; Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Yokohama, Kanagawa 230-0045, Japan.
National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan.
Bioorg Med Chem. 2023 May 15;86:117293. doi: 10.1016/j.bmc.2023.117293. Epub 2023 Apr 25.
Developing highly active proteolysis-targeting chimeras (PROTACs) requires investigating a variety of ubiquitin ligase (E3 ligase) ligands and linker structures as well as their lengths. In this study, we developed a solid-phase synthesis method that affords PROTAC design diversity. We expanded the E3 ligand range to include Von Hippel-Lindau (VHL) and inhibitor of apoptosis protein (IAP) ligands because only the cereblon (CRBN) ligand thalidomide and its derivatives have been investigated for solid-phase synthesis of PROTACs. Moreover, we examined the suitability of a polyethylene glycol (PEG) rather than an alkyl linker used in our previous study for synthesizing PROTACs. Facile and rapid solid-phase synthesis methods using the above E3 ligands for developing PROTACs targeting bromodomain-containing protein 4 (BRD4) were accomplished. Western blotting analysis revealed that minor differences in the E3 ligand and linker type significantly affected the activity of the synthesized PROTACs. Our solid-phase PROTAC synthesis methods enable rapid synthesis of multiple PROTACs with various combinations of ligands for the protein-of-interest and E3 ligands and linkers that connect these ligands.
开发高活性的蛋白水解靶向嵌合体(PROTAC)需要研究多种泛素连接酶(E3连接酶)配体、连接子结构及其长度。在本研究中,我们开发了一种能够提供PROTAC设计多样性的固相合成方法。我们扩展了E3配体的范围,纳入了冯·希佩尔-林道(VHL)和凋亡抑制蛋白(IAP)配体,因为在PROTAC的固相合成研究中,仅考察了大脑神经酰胺(CRBN)配体沙利度胺及其衍生物。此外,我们研究了聚乙二醇(PEG)而非我们之前研究中用于合成PROTAC的烷基连接子的适用性。利用上述E3配体开发靶向含溴结构域蛋白4(BRD4)的PROTAC的简便且快速的固相合成方法得以实现。蛋白质印迹分析表明,E3配体和连接子类型的微小差异显著影响了合成的PROTAC的活性。我们的固相PROTAC合成方法能够快速合成多种PROTAC,这些PROTAC具有针对目标蛋白的配体、E3配体以及连接这些配体的连接子的各种组合。